BioNTech SE BNTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -171.56% | -414.65% | -78.40% | -76.39% | -26.46% |
| Total Depreciation and Amortization | 190.76% | 215.00% | 77.27% | 23.80% | 19.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,886.11% | 401.34% | 476.22% | 286.72% | 85.55% |
| Change in Net Operating Assets | -243.00% | 195.13% | 90.42% | -50.52% | -92.25% |
| Cash from Operations | -13.97% | 142.81% | 455.36% | 193.17% | -114.59% |
| Capital Expenditure | -24.09% | -5.26% | 28.57% | 36.19% | 40.68% |
| Sale of Property, Plant, and Equipment | 57.76% | 356.99% | 259.20% | 301.35% | 859.51% |
| Cash Acquisitions | 428.84% | 473.15% | 473.15% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -34.61% | -165.71% | -169.14% | -55.36% | 119.61% |
| Cash from Investing | -7.75% | -173.42% | -179.50% | -32.79% | 113.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -29.19% | -40.90% | -7.51% | -25.49% | 9.82% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -646.76% | -172.11% | 74.30% | -20.42% | 8.70% |
| Foreign Exchange rate Adjustments | 77.34% | -672.93% | -99.89% | -289.94% | 88.51% |
| Miscellaneous Cash Flow Adjustments | 341.75% | 34.31% | -40.50% | 136.56% | -109.51% |
| Net Change in Cash | -72.31% | -332.45% | -121.68% | -18.60% | 111.43% |